Publications
Preprints
About UCL Open: Env.
Aims and Scope
Editorial Board
Indexing
APCs
How to cite
Publishing policies
Editorial policy
Peer review policy
Equality, Diversity & Inclusion
About UCL Press
Contact us
Information for authors
How it works
Benefits of publishing with us
Submit
How to submit
Preparing your manuscript
Article types
Open Data
ORCID
APCs
Contributor agreement
Information for reviewers
Review process
How to peer review
Peer review policy
Register Dashboard
Search

Browse
Publications
Preprints
About
About UCL Open: Env.
Aims and Scope
Editorial Board
Indexing
APCs
How to cite
Publishing policies
Editorial policy
Peer review policy
Equality, Diversity & Inclusion
About UCL Press
Contact us
For authors
Information for authors
How it works
Benefits of publishing with us
Submit
How to submit
Preparing your manuscript
Article types
Open Data
ORCID
APCs
Contributor agreement
For reviewers
Information for reviewers
Review process
How to peer review
Peer review policy
My ScienceOpen

Register Dashboard
Search
6
views
0
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,950
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Book: not found

      Allergan and Editas Medicine announce dosing of first patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

      Author(s):
      Publication date:

      Read this book at

      Bookmark
          There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Data availability:

          Comments

          Comment on this book